Intranasal Delivery of Anti-Apoptotic siRNA Complexed with Fas-Signaling Blocking Peptides Attenuates Cellular Apoptosis in Brain Ischemia
-
Published:2024-02-18
Issue:2
Volume:16
Page:290
-
ISSN:1999-4923
-
Container-title:Pharmaceutics
-
language:en
-
Short-container-title:Pharmaceutics
Author:
Chung Kunho12ORCID, Ullah Irfan13ORCID, Yi Yujong1ORCID, Kang Eunhwa1, Yun Gyeongju1ORCID, Heo Seoyoun1, Kim Minkyung1, Chung Seong-Eun1, Park Seongjun1, Lim Jaeyeoung1, Lee Minhyung1, Rhim Taiyoun1ORCID, Lee Sang-Kyung1ORCID
Affiliation:
1. Department of Bioengineering and Institute of Nanoscience and Technology, Hanyang University, Seoul 04763, Republic of Korea 2. Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44106, USA 3. Department of Internal Medicine, Yale University, New Haven, CT 06520, USA
Abstract
Ischemic stroke-induced neuronal cell death leads to the permanent impairment of brain function. The Fas-mediating extrinsic apoptosis pathway and the cytochrome c-mediating intrinsic apoptosis pathway are two major molecular mechanisms contributing to neuronal injury in ischemic stroke. In this study, we employed a Fas-blocking peptide (FBP) coupled with a positively charged nona-arginine peptide (9R) to form a complex with negatively charged siRNA targeting Bax (FBP9R/siBax). This complex is specifically designed to deliver siRNA to Fas-expressing ischemic brain cells. This complex enables the targeted inhibition of Fas-mediating extrinsic apoptosis pathways and cytochrome c-mediating intrinsic apoptosis pathways. Specifically, the FBP targets the Fas/Fas ligand signaling, while siBax targets Bax involved in mitochondria disruption in the intrinsic pathway. The FBP9R carrier system enables the delivery of functional siRNA to hypoxic cells expressing the Fas receptor on their surface—a finding validated through qPCR and confocal microscopy analyses. Through intranasal (IN) administration of FBP9R/siCy5 to middle cerebral artery occlusion (MCAO) ischemic rat models, brain imaging revealed the complex specifically localized to the Fas-expressing infarcted region but did not localize in the non-infarcted region of the brain. A single IN administration of FBP9R/siBax demonstrated a significant reduction in neuronal cell death by effectively inhibiting Fas signaling and preventing the release of cytochrome c. The targeted delivery of FBP9R/siBax represents a promising alternative strategy for the treatment of brain ischemia.
Funder
Korea Research Foundation
Reference78 articles.
1. The global burden of ischemic stroke: Findings of the GBD 2010 study;Bennett;Glob. Heart,2014 2. Ayehu, G.W., Yitbarek, G.Y., Jemere, T., Chanie, E.S., Feleke, D.G., Abebaw, S., Zewde, E., Atlaw, D., Agegnehu, A., and Mamo, A. (2022). Case fatality rate and its determinants among admitted stroke patients in public referral hospitals, Northwest, Ethiopia: A prospective cohort study. PLoS ONE, 17. 3. Truelsen, T., Begg, S., and Mathers, C. (2000). The Global Burden of Cerebrovascular Disease, World Health Organisation. 4. Bersano, A., and Gatti, L. (2023). Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. Int. J. Mol. Sci., 24. 5. Thresholds of focal cerebral ischemia in awake monkeys;Jones;J. Neurosurg.,1981
|
|